Retatrutide: The Practical Guide
Reviewed against Phase 2 (NEJM 2023) and Phase 3 TRIUMPH data · Updated June 2026
What it actually does, the two reasons people use it, the real dosing debates, and the mistakes that wreck otherwise good protocols.
What retatrutide actually is
Retatrutide is a 39 amino acid synthetic peptide that activates three receptors at once. Its half life is roughly six days, which is why once weekly dosing is what the trials used. The three targets each pull in a different direction:
GLP-1
Reduces appetite and slows gastric emptying. Cuts calories in.
GIP
Supports insulin sensitivity, satiety, and healthy fat cell function.
Glucagon
Raises energy expenditure and burns fat in the liver. Adds calories out.
The difference
Two arms reduce intake. One increases output. That third arm is what nothing else on the market currently does.
Why the glucagon arm changes the picture
Glucagon is usually associated with raising blood sugar, but that is not the action that matters here. The blood sugar effect is offset by the GLP-1 and GIP arms keeping insulin secretion robust, which leaves the fat burning side largely unopposed. In the liver that signaling increases fat oxidation, suppresses the creation of new fat from carbohydrate, raises resting energy expenditure, and shifts the body away from storing triglycerides. This is the mechanism behind the liver fat reductions north of 80 percent that have shown up in trials.
Two reasons people use it, two different protocols
The single most important decision is which user you are, because it drives everything else.
The weight loss user
BMI over 27, often over 30. Wants meaningful fat loss, typically a 15 to 30 percent reduction in body weight. Higher doses, full titration, longer protocols.
The longevity user
Normal or near normal BMI. Wants to optimize metabolic markers: insulin sensitivity, liver fat, lipids, blood pressure, inflammation. Lower doses, sometimes microdosed, shorter or maintenance protocols.
If you are a lean longevity user, do not run the obesity protocol. Different goals, different doses, different timelines.
The weight loss evidence
Across the dose range studied, the response climbs steadily, and at the top dose it set a record for the class.
| Dose and duration | Mean weight loss |
|---|---|
| 1 mg, 48 weeks | 8.7% |
| 4 mg, 48 weeks | 17.1% |
| 8 mg, 48 weeks | 22.8% |
| 12 mg, 48 weeks | 24.2% |
| 12 mg, TRIUMPH-4, 68 weeks | 28.7% |
28.7 percent mean weight loss at 68 weeks on 12 mg is the largest mean weight loss reported in any Phase 3 obesity trial. Notably, the curve had not plateaued at 48 weeks. With semaglutide and tirzepatide, plateau is usually the rule by 60 to 72 weeks.
The metabolic case, which matters more for lean users
The part that gets less attention is the metabolic improvement. At 12 mg in Phase 2 the marker changes were striking.
Fasting insulin dropped by half or more at higher doses. Inflammatory markers such as hsCRP improved, and HbA1c fell about 0.4 points in non-diabetics.
Why longevity users care
Insulin resistance, liver fat, and chronic inflammation sit at central nodes in the aging network, and retatrutide hits all of them. Chronically elevated insulin suppresses AMPK, impairs autophagy, and pushes mTOR and oxidative stress up. Liver fat drives systemic insulin resistance and tracks with accelerated aging on methylation clocks. Visceral fat, the fat you cannot see, drives inflammatory signaling. ApoB is the strongest causal lipid marker for atherosclerosis, and a 24 percent drop is a real reduction in cardiovascular risk. For someone optimizing healthspan, that is more interesting than the scale.
High ApoB or non-HDL despite a clean diet, persistent liver fat on imaging despite a lean appearance, visceral fat on DXA out of proportion to total body fat, insulin resistance markers such as a HOMA-IR over 1.5, or a strong family history of type 2 diabetes, cardiovascular, or liver disease. These are conversations to have with a clinician who can order the right baseline workup.
Dosing: the debates that actually matter
The standard titration
The schedule below is what every TRIUMPH trial used and is close to what the eventual label will probably look like. It was designed for significant obesity, so lean users should not run it.
| Weeks | Weekly dose |
|---|---|
| 1 to 4 | 2 mg |
| 5 to 8 | 4 mg |
| 9 to 12 | 6 mg |
| 13 to 17 and beyond | 9 mg, then 12 mg, or hold at 9 mg |
A 4 mg maintenance dose was studied as a lower burden long term option. Holding at any step if tolerability requires it is strategy, not failure.
Once weekly versus split dosing
This is the most argued question online, and the honest answer is that both work. Once weekly is the clinical protocol with known efficacy and safety, but it produces a sawtooth pattern with a high peak in the first day or two and a low trough by day six or seven, and a peak to trough ratio around four to one. Some people get an end of week hunger spike. Splitting the dose into twice weekly cuts the peak concentration by roughly 28 percent, smooths appetite suppression, and is reported to reduce nausea on injection day. The tradeoff is that split dosing has no trial validation behind it, only pharmacokinetic modeling. Once weekly is the right starting point for almost everyone, and you can switch later if peaks become punishing. The arithmetic is simple: 4 mg per week becomes 2 mg twice weekly, 8 mg becomes 4 mg twice weekly, and so on.
How far to push the dose
This is where the community makes its biggest dosing mistake. The dose response curve flattens between 8 and 12 mg: that last step buys about 1.4 additional percentage points of weight loss for 50 percent more drug and meaningfully more side effect burden.
For most users 8 mg is a sensible ceiling. 12 mg makes sense for severe obesity or for non response at lower doses. Pushing past your tolerance ceiling is the wrong move. Holding longer at the dose that works usually beats chasing a higher number.
The lean user protocol
For non-obese users targeting markers rather than the scale, the goal is metabolic improvement, not aggressive appetite suppression. A common approach is to start at 1 mg per week rather than 2, hold for four weeks to assess, and only move to 2 mg if needed. Many lean users never go above 2 to 4 mg, and some run 0.5 mg twice weekly indefinitely for maintenance. Insulin sensitivity, liver fat, and lipid effects are well preserved at these lower doses.
Morning versus night
With a six day half life, plasma concentration changes by less than 15 percent across any given 24 hours, so there is no pharmacokinetically meaningful best time of day. What actually matters is that the 4 to 24 hour window after injection is when nausea and fatigue tend to peak. Pick the timing that puts that window where it bothers you least, then stay consistent. A common pattern is to inject at night during titration so you sleep through the worst of it, then switch to morning at maintenance once side effects settle.
Side effects and what helps
GI symptoms are the most common, mostly during titration, and they mostly resolve. In the trials, nausea ran around 27 percent at higher doses, diarrhea around 23 percent, and vomiting around 18 percent, with constipation, heartburn, and reflux also reported.
What tends to help: slower titration by extending each step to five or six weeks, smaller and more frequent meals, good hydration, low fat meals on injection day, and switching from once weekly to twice weekly to smooth the peak. For severe nausea, a clinician may prescribe an antiemetic. The core rule is to hold the dose rather than climb until symptoms settle.
The heart rate question
Resting heart rate rises about 5 to 10 bpm at higher doses, larger than the 2 to 4 bpm seen with semaglutide or tirzepatide, driven by GLP-1 chronotropy plus direct glucagon receptor effects. It tends to peak around week 24 and then partially decline. Track it, since most wearables do this passively. A persistent resting heart rate over 100 bpm warrants pausing and getting evaluated. Net cardiovascular effects look favorable on surrogate markers, but long term outcomes data is not expected until the 2028 to 2029 window.
The dysesthesia signal
A newer and less familiar effect is dysesthesia: tingling, mild burning, or altered skin sensation without any visible skin findings. It appears dose related and more common at 12 mg, reported in roughly 21 percent of the 12 mg arm in TRIUMPH-4 versus single digits in other studies. Most cases are mild and few people discontinue. If it shows up, holding at 9 mg rather than pushing to 12 mg is a reasonable call, since the small extra weight loss is not worth chronic discomfort.
Medications that need active management
This is the part to plan with a prescriber before you start, not to manage on your own. Because retatrutide drives metabolic change quickly, several common medications can effectively become too strong, and the right adjustments depend on your labs and your clinician’s judgment.
- Antihypertensives. Blood pressure can fall meaningfully. In trials, a large share of participants reduced or stopped at least one BP medication. This needs close monitoring.
- Insulin and sulfonylureas. Improving insulin sensitivity while appetite drops raises real hypoglycemia risk. Dosing of these needs to be reviewed by your prescriber at the start.
- Statins. As LDL falls, high intensity statin dosing may warrant review.
- Levothyroxine. Weight change shifts thyroid hormone needs. Rechecking TSH around 12 weeks is sensible.
- Oral contraceptives. Efficacy may be reduced during titration and dose increases. Discuss backup or non-oral methods with your clinician.
Protein and training are not optional
This is the single biggest mistake people make. Someone losing 25 percent of body weight will lose meaningful lean mass along with fat, often 5 to 7 kg of it at that magnitude. That is normal, and it is also largely avoidable.
Protein
Aim for 1.2 g/kg minimum, 1.6 g/kg as a target, calculated against reference body weight, or lean body mass for lean users.
Resistance training
Two to three sessions per week, full body or upper-lower, with progressive overload. Without it, you get a smaller and weaker version of yourself.
Appetite suppression makes hitting protein targets genuinely hard, because the drug has hijacked the hunger signal you would normally rely on. Eat to a number, not to satiety. Protein shakes, Greek yogurt, cottage cheese, lean meats, and protein-first eating all help when volume is limited.
The metrics that actually matter
Stop weighing yourself daily and start tracking what the drug is really doing. Get a baseline before starting, then recheck around 12 weeks, 24 weeks, and every six months.
- Body composition: DXA for body composition and visceral fat, plus resting heart rate and blood pressure.
- Metabolic: comprehensive metabolic panel, HbA1c, fasting insulin, HOMA-IR, hsCRP.
- Lipids: full panel including ApoB and Lp(a).
- Hormones: TSH, free T3, free T4, and for men total and free testosterone, estradiol, and SHBG.
- Longevity focus: liver imaging or FibroScan, especially for lean users.
For a longevity-focused user, that is the better outcome. ApoB down 30 points is a real reduction in atherosclerosis risk. Normalized liver enzymes mean steatosis is reversing. Insulin way down is the longevity signal. Weight loss is one effect of this drug, not the only one, and often not the most important.
How long to stay on, and the regain reality
Every drug in this class shows substantial weight regain after stopping. Pooled analyses put it around 76 percent of lost weight regained, with a half life of roughly 23 weeks. The honest framing is that stopping is not graduation, it is reverting, and you should plan for that from day one.
| Profile | Typical approach |
|---|---|
| Severe metabolic disease | Indefinite, like an antihypertensive |
| Weight loss goal | Run to goal, then a maintenance dose while lifestyle locks in |
| Longevity optimization | A focused 6 to 12 month protocol, then taper to maintenance or off, rerun if markers drift |
Plan the taper before you start. A clear “I will run this for six months, then taper” is a plan. “I will keep going until something changes” is drift. Many people transition to a low maintenance dose rather than stopping cold, which preserves most of the metabolic benefit at low cost.
The common mistakes
- Chasing a higher dose past your tolerance ceiling.
- Skipping protein and resistance training. The drug does not protect lean mass on its own.
- Daily weighing and reacting emotionally to noise.
- Stopping cold with no maintenance plan, then panicking when weight returns.
- Treating it as a replacement for sorting out hormones, sleep, and training rather than a complement.
- Running the obesity protocol as a lean longevity user.
- Not tracking metabolic markers, which are what this drug does best.
The framework, compressed
- Decide your goal first: weight loss or longevity. It sets the dose.
- Sort the fundamentals first: hormones if indicated, thyroid, sleep, a training base, protein.
- Start low, 1 to 2 mg weekly, and hold four weeks before reassessing.
- Titrate slowly. Most users find their working dose at 4 to 8 mg.
- Switch to twice weekly if peaks become punishing.
- Track the metrics that matter, not just weight.
- Plan your taper before you start.
- Pair with adequate protein and resistance training. Non-negotiable.
- Consider a maintenance dose for chronic benefit rather than full discontinuation.
- Adjust based on your labs and your clinician, not online opinions.
The bottom line
Retatrutide is the most powerful metabolic compound on the horizon, for weight loss and for nearly every downstream marker of metabolic health. But the framework still wins. The person who gets extraordinary results sorts the fundamentals, trains, eats enough protein, and uses the drug as a focused tool. The person who gets disappointing results treats it as a magic bullet for an unoptimized life, gets thin, gets mediocre labs, and has to start over. Be the first kind.
To learn more about GLP-1s and other peptides, join our free Skool Group here.